Biopharmaceutics Risk Assessment to Guide Dissolution Method Development for Solid Oral Dosage Forms

Min Li, PhD, Acting Biopharmaceutics Lead for the Division of Biopharmaceutics, discusses the scientific and risk-based framework associated with the Agency’s evaluation of invitro dissolution method development for generic immediate-release, extended-release and delayed-release solid oral drug products.
Learn more at: www.fda.gov/drugs/news-events...
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
 
Upcoming Training - www.fda.gov/cdersbia
SBIA Listserv - public.govdelivery.com/accoun...
SBIA 2021 Playlist - • 2021 CDER Small Busine...
SBIA LinkedIn: / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cdersbialearn
Twitter - / fda_drug_info
Email - [e-mail]  
Phone - [phone] I [phone]